Literature DB >> 12771596

Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center.

David K Warren1, Sunita J Shukla, Margaret A Olsen, Marin H Kollef, Christopher S Hollenbeak, Michael J Cox, Max M Cohen, Victoria J Fraser.   

Abstract

OBJECTIVE: To determine the attributable cost of ventilator-associated pneumonia from a hospital-based cost perspective, after adjusting for potential confounders.
DESIGN: Patients admitted between January 19, 1998, and December 31, 1999, were followed prospectively for the occurrence of ventilator-associated pneumonia. Hospital costs were defined by using the hospital cost accounting database.
SETTING: The medical and surgical intensive care units at a suburban, tertiary care hospital. PATIENTS: Patients requiring >24 hrs of mechanical ventilation.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We measured occurrence of ventilator-associated pneumonia, in-hospital mortality rate, total intensive care unit (ICU) and hospital lengths of stay (LOS), and total hospital cost per patient. Ventilator-associated pneumonia occurred in 127 of 819 patients (15.5%). Compared with uninfected, ventilated patients, patients with ventilator-associated pneumonia had a higher Acute Physiology and Chronic Health Evaluation II score on admission (p <.001) and were more likely to require multiple intubations (p <.001), hemodialysis (p <.001), tracheostomy (p <.001), central venous catheters (p <.001), and corticosteroids (p <.001). Patients with ventilator-associated pneumonia were more likely to be bacteremic during their ICU stay (36 [28%] vs. 22 [3%]; p <.001). Patients with ventilator-associated pneumonia had significantly higher unadjusted ICU LOS (26 vs. 4 days; p <.001), hospital LOS (38 vs. 13 days; p <.001), mortality rate (64 [50%] vs. 237 [34%]; p <.001), and hospital costs (70,568 dollars vs. 21,620 dollars, p <.001). Multiple linear regression, controlling for other factors that may affect costs, estimated the attributable cost of ventilator-associated pneumonia to be 11,897 dollars (95% confidence interval = 5,265 dollars-26,214 dollars; p <.001).
CONCLUSIONS: Patients with ventilator-associated pneumonia had significantly longer ICU and hospital LOS, with higher crude hospital cost and mortality rate compared with uninfected patients. After we adjusted for underlying severity of illness, the attributable cost of ventilator-associated pneumonia was approximately 11,897 dollars.

Entities:  

Mesh:

Year:  2003        PMID: 12771596     DOI: 10.1097/01.CCM.0000063087.93157.06

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  92 in total

1.  Physical therapy management of ventilated patients with acute respiratory distress syndrome or severe acute lung injury.

Authors:  Frank Chung; Dan Mueller
Journal:  Physiother Can       Date:  2011-04-13       Impact factor: 1.037

2.  Assessment of Critical Care Provider's Application of Preventive Measures for Ventilator-Associated Pneumonia in Intensive Care Units.

Authors:  Masoumeh Bagheri-Nesami; Maryam Amiri-Abchuyeh; Afshin Gholipour-Baradari; Jamshid Yazdani-Cherati; Attieh Nikkhah
Journal:  J Clin Diagn Res       Date:  2015-08-01

Review 3.  Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Antibiotic prescribing for ventilator-associated pneumonia: get it right from the beginning but be able to rapidly deescalate.

Authors:  Jean Chastre
Journal:  Intensive Care Med       Date:  2005-09-07       Impact factor: 17.440

Review 5.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

7.  Incidence and risk factors for ventilator-associated pneumonia after major heart surgery.

Authors:  Javier Hortal; Maddalena Giannella; Maria Jesús Pérez; José Maria Barrio; Manuel Desco; Emilio Bouza; Patricia Muñoz
Journal:  Intensive Care Med       Date:  2009-06-26       Impact factor: 17.440

Review 8.  Costs of hospital-acquired infection and transferability of the estimates: a systematic review.

Authors:  H Fukuda; J Lee; Y Imanaka
Journal:  Infection       Date:  2011-03-22       Impact factor: 3.553

9.  Pulmonary Delivery of Vancomycin Dry Powder Aerosol to Intubated Rabbits.

Authors:  Bradley P Sullivan; Nashwa El-Gendy; Christopher Kuehl; Cory Berkland
Journal:  Mol Pharm       Date:  2015-05-06       Impact factor: 4.939

10.  Bactericidal effects of silver plus titanium dioxide-coated endotracheal tubes on Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  Keiko M Tarquinio; Nikhil K Kothurkar; Dharendra Y Goswami; Ronald C Sanders; Arno L Zaritsky; Ann Marie LeVine
Journal:  Int J Nanomedicine       Date:  2010-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.